Chintan Dave

Professor Chintan Dave is dedicated to advancing the understanding of pharmacoepidemiology and treatment sciences. As an Assistant Professor in Pharmacy Practice and Administration at the Ernest Mario School of Pharmacy, Rutgers University-New Brunswick, he brings a wealth of knowledge and expertise to his role. His academic journey began with a Doctor of Pharmacy (PharmD) degree from the St. Louis College of Pharmacy, followed by a PhD in Pharmacoepidemiology from the University of Florida. Further honing his expertise, Dr. Dave completed a post-doctoral fellowship at the prestigious Harvard Medical School. Dr. Dave's research interests are diverse and impactful, focusing on the Comparative Safety and Effectiveness of Pharmaceuticals. He is particularly interested in the safety and cardiovascular effectiveness of sodium-glucose co-transporter-2 inhibitors, a class of medications used in the management of type 2 diabetes. His work in cardiometabolic and geriatric pharmacoepidemiology is crucial in understanding the implications of pharmaceutical treatments in these populations. At the Institute for Health Sciences in New Brunswick, NJ, Dr. Dave applies his research to real-world settings, ensuring that his findings contribute to the improvement of health services and patient outcomes. His commitment to internal medicine and the broader field of health services research underscores his dedication to enhancing the safety and effectiveness of pharmaceutical interventions. Dr. Dave's contributions to the field are not only academic but also practical, as he actively engages in research that informs clinical practice and policy. His work is instrumental in guiding healthcare professionals and policymakers in making informed decisions about pharmaceutical treatments, ultimately benefiting patient care and public health. Through his teaching, research, and clinical practice, Dr. Chintan Dave continues to make significant strides in the field of pharmacy, influencing both current and future generations of healthcare professionals. His dedication to research and education exemplifies his commitment to advancing the field of pharmacoepidemiology and improving health outcomes for diverse populations.